GPC Biotech Drug Fails Trial
GPC Biotech (GPCB) tanked and Spectrum Pharmaceuticals (SPPI) took a hit after saying Wednesday that the phase III SPARC trial on prostate cancer drug Orplanta (satraplatin) failed to show a survival benefit.
GPC licenses the drug for hormone-refractory prostate cancer from Spectrum. In July, the Oncology Drugs Advisory Committee (ODAC) recommended that the Food and Drug Administration wait to approve Orplanta until overall survival data from the SPARC trial were available, questioning the methodology of research that was submitted. Subsequently, GPC withdrew its new-drug application for accelerated approval.
Orplanta was the lead product candidate for GPC, which has an antibody in early-stage development for the treatment of lymphoid cancers, but no other mid- or late-stage prospects. GPC's shares fell $6.64, or 58%, to $4.80 -- $5.45 below its 52-week low. Spectrum, meanwhile, fell 51 cents, or 12.3%, to $3.65.
After removing Orplanta-related revenue and milestones from his model for Spectrum Pharmaceuticals, Rodman & Renshaw analyst Reni Benjamin arrived at a 12-month price target of $6. However, he seemed optimistic about Spectrum's bigger picture, noting a report: "While we are disappointed with the SPARC trial outcome, we believe Spectrum has a strong, advanced stage product portfolio that will generate shareholder value in the long-term."Specifically, Benjamin is looking at the advancement of EOquin in two late-stage trials for low-risk superficial bladder cancer and a potential international partner for that program, and potential IIb data from the ongoing ozarelix trial in benign prostatic hyperplasia (BPH) in the second quarter of 2008 with the potential to initiate late-stage trials in 2008. Shares of Pharmion (PHRM), which has the right to market the drug in Europe, were seemingly unaffected. The stock rose $1.22, or 2.7%, to $48.59. Pharmion is set to release third-quarter earnings today after the close.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV